Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Immunodiagnostics group Oncimmune Holdings said it had gathered positive results from a study in Scotland of its early lung-cancer detection technology.
The study recruited 12,210 patients, each of whom were followed up for a minimum of two years.
'The company is pleased to report that the study met its primary endpoint showing that the use of EarlyCDT-Lung with subsequent X-ray and computerised tomography scan reduced the incidence of patients with late-stage lung cancer or unclassified presentation at diagnosis, compared to standard clinical practice,' the company said.
A submission of the full study findings was being prepared for a leading peer-reviewed medical publication and was expected to be published in the third quarter.
At 9:01am: (LON:ONC) Oncimmune Holdings Plc share price was +7.5p at 100p